JC02 Rec'd PCT/PTO 27 MAR 2002

FORM PTO-1390 (REV. 10-95) OMB 0651-0027 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER	7821
U.S. APPLICATION NO. (if known, see 37 CFR 1.5)	10/089329
INTERNATIONAL APPLICATION NO.	PCT/US00/27503
INTERNATIONAL FILING DATE	05 October 2000
PRIORITY DATE CLAIMED	08 October 1999

TITLE OF INVENTION

Process For Making Boc-Protected 3-Aminohydantoins/Thiohydantoins and 3-Aminodihydrouracils/Dihydrothiouracils

APPLICANT(S) FOR DO/EO/US

WU, Shengde et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.

1. [x] This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. [] This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. [] This express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. [x] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. [x] A copy of the International Application was filed (35 U.S.C. 371(c)(2))
   a. [] is transmitted herewith (required only if not transmitted by the International Bureau).
   b. [] has been transmitted by the International Bureau.
   c. [x] is not required, as the application was filed in the United States Receiving Office (RO/US).
6. [] A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. [x] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. [] are transmitted herewith (required only if not transmitted by the International Bureau).
   b. [] have been transmitted by the International Bureau.
   c. [] have not been made; however, the time limit for making such amendments has NOT expired.
   d. [x] have not been made and will not be made.
8. [] A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. [x] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. [] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. [] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. [] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. [x] A FIRST preliminary amendment.
    [] A SECOND or SUBSEQUENT preliminary amendment.
14. [] A substitute specification.
15. [x] A change of power of attorney and/or address letter.
16. [] Other items or information:

"Express Mail" mailing label number EL483621598US

Date of Deposit 27 March 2002

I hereby certify that this paper/fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to The Assistant Commissioner of Patents, Washington, D.C. 20231.

Administrator for Mailing Application

Virginia C. Byrd

Signature

10089329 032502
JC13 Rec'd PCT/PTO 27 MAR 2002

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
10/089329	PCT/US00/27503	7821

	CALCULATIONS PTO USE ONLY	
ENTER APPROPRIATE BASIC FEE AMOUNT =	$740	
Surcharge of $130.00 for furnishing the oath or declaration later than | | 20 | | 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	$0	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	25-20=	25	x $18.00	$90	
Independent Claims	4-3=	1	x $84.00	$84	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			$280.00	$0	
TOTAL OF ABOVE CALCULATIONS =				$914	
Processing fee of $130.00 for furnishing the English translation later than | | 20 | | 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				$0	
TOTAL NATIONAL FEE =				$914	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28,3.31). $40.00 per property +				$0	
TOTAL FEES ENCLOSED =				$914	
				Amount to be refunded	$
				charged	$

a. [ ] A check in the amount of $ ____ to cover the above fees is enclosed.

b. [x] Please charge my Deposit Account No. 16-2480 in the amount of $ 914 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. [x] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 16-2480 . A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

R. S. Echler, Patent Agent
Customer Number 27752



Signature

T. David Reed
Name

32,931
Registration Number

10/089329
JC13 Rec'd PCT/PTO 27 MAR 2002

Case 7821

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Matter of:

U.S. National Phase Entry
Under 35 USC § 371 from
the International Application of :
Shengde Wu et al. :
Int'l Application No. PCT/US00/27503 :
Filed in the RO/US on 05 October 2000 :
Entitled: Process for Making Boc-Protected 3-Aminohydantoins/Thiohydantoins and 3-Aminodihydrouracils/Dihydrothiouracils

PRELIMINARY AMENDMENT UNDER 37 CFR § 1.112

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to Examination and computation of the fees for entering the captioned International Application into the U.S. National Phase, please preliminarily amend the above-identified application as follows and consider the following Remarks.

AMENDMENTS

IN THE SPECIFICATION

At page 12, at line 4 please delete the word "or" and at line 11 please delete the first occurrence of the word "or."

At page 15, line 9 and 10, please delete the chemical name "carbamic acid, Tetrahydro-5,7-dioxoimidazol[5,1-b]thiazo-6(5*H*)-yl)-, 1,1-dimethylethyl ester" and insert therefor --carbamic acid, tetrahydro-5,7-dioxoimidazol[5,1-b]thiazol-6(5*H*)-yl)-, 1,1-dimethylethyl ester--.

At page 17, line 12, please delete "pipercolinate" and insert therefor --pipecolinate--.

At page 17, line 31 and 32, please delete the chemical name "carbamic acid, (3-(2-furanylmethyl)tetrahydro-2-oxo-6-thioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester" and insert therefor --carbamic acid, (3-(2-furanylmethyl)tetrahydro-6-oxo-2-thioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester--.

IN THE CLAIMS

Please cancel Claims 1 and 2 and insert therefor new Claims 3-27 as follows.

3. (New) A method for making a hydantoin or thiohydantoin having the formula:



wherein X is oxygen or sulfur, R_1 is hydrogen, alkyl, a heterocyclic ring, an aromatic ring, or a heteroaromatic ring; R_2 is hydrogen, alkyl, a heterocyclic ring, an aromatic ring, or a heteroaromatic ring; or R_1 and R_2 can be taken together to form a fused heterocyclic ring, a fused aromatic ring, or a fused heteroaromatic ring with the hydantoin or thiohydantoin ring; said method comprising the steps of:

a) reacting a hydrazine compound having the formula:



with an amino acid ester having the formula:



to form a reaction mixture; and

b) heating said reaction mixture to form said hydantoin or thiohydantoin.

4. (New) A method according to Claim 3 wherein X is oxygen.

5. (New) A method according to Claim 3 wherein said R_1 is a unit selected from the group consisting of phenyl, 4-methoxyphenyl, benzyl, 4-methoxybenzyl, 2-furanylmethyl, 1,3-benzodioxol-5-ylmethyl, (5-methoxy-1*H*-indol-3-yl)ethyl, (1*H*-imidazol-1-yl)ethyl, (1*H*-imidazol-4-yl)ethyl, [(5-nitro-2-pyridinyl)amino]ethyl, 2-(1-piperidinyl)ethyl, (1-methyl-2-pyrrolidinyl)ethyl, (2-methyl-1-piperidinyl)propyl, 3-(1-piperidinyl)propyl, 3-(4-morphilinyl)propyl, 3-(2-oxo-1-pyrrolidinyl)propyl, (6,6-dimethylbicyclo[3.1.1]hept-3-yl)methyl, 1-(phenylmethyl)-4-piperidnyl, and 2-furanylmethyl.

6. (New) A method according to Claim 3 wherein said amino acid ester is selected from the group consisting of a benzyl, methyl, or ethyl ester of 2-pipecoline carboxylate, proline, 4-hydroxyproline, 1,2,3,4-tetrahydro-3-isoquinolinecarboxylate, thiozolidine-2-carboxylate, and mixtures thereof.

7. (New) A method according to Claim 3 wherein R_2 is hydrogen or methyl.

8. (New) A method according to Claim 3 wherein said process is conducted in the presence of a solvent selected from the group consisting of tetrahydrofuran, dimethylformamide, dioxane, methylene chloride, and mixtures thereof.

9. (New) A method according to Claim 3 wherein step (b) is conducted at a temperature of from 60 °C to 70 °C.

10. (New) A method according to Claim 3 wherein prior to step (a) said process comprises a step of forming said hydrazine compound having the formula:



wherein said step comprises reacting tert-butoxycarbonyl hydrazine with carbonyldiimidazole or thiocarbonyldiimidazole to form said hydrazine compound.

11. (New) A method according to Claim 10 wherein said hydrazine compound is used in step (a) directly without further purification.

12. (New) A method according to Claim 3 further comprising the step of isolating said hydantoin or thiohydantoin.

13. (New) A method according to Claim 8 wherein said process further comprises the step of removing said solvent.

14. (New) A method for making a 3-aminodihydrouracil or 3-aminodihydrothiouracil having the formula:



wherein X is oxygen or sulfur, R_1 is hydrogen, alkyl, a heterocyclic ring, an aromatic ring, or a heteroaromatic ring; R_2 is hydrogen, alkyl, a heterocyclic ring, an aromatic ring, or a heteroaromatic ring; or R_1 and R_2 can be taken together to form a fused heterocyclic ring, a

fused aromatic ring, or a fused heteroaromatic ring with the 3-aminodihydrouracil or 3-aminodihydrothiouracil ring; said method comprising the steps of:

a) reacting a hydrazine compound having the formula:



with an amino acid ester having the formula:



to form a reaction mixture; and

b) heating said reaction mixture to form said 3-aminodihydrouracil or 3-aminodihydrothiouracil.

15. (New) A method according to Claim 14 wherein X is oxygen.

16. (New) A method according to Claim 14 wherein said R_1 is a unit selected from the group consisting of phenyl, 4-methoxyphenyl, benzyl, 4-methoxybenzyl, 2-furanylmethyl, 1,3-benzodioxol-5-ylmethyl, (5-methoxy-1*H*-indol-3-yl)ethyl, (1*H*-imidazol-1-yl)ethyl, (1*H*-imidazol-4-yl)ethyl, [(5-nitro-2-pyridinyl)amino]ethyl, 2-(1-piperidinyl)ethyl, (1-methyl-2-pyrrolidinyl)ethyl, (2-methyl-1-piperidinyl)propyl, 3-(1-piperidinyl)propyl, 3-(4-morphilinyl)propyl, 3-(2-oxo-1-pyrrolidinyl)propyl, (6,6-dimethylbicyclo[3.1.1]hept-3-yl)methyl, 1-(phenylmethyl)-4-piperidnyl, and 2-furanylmethyl.

17. (New) A method according to Claim 14 wherein said amino acid ester is selected from the group consisting of a benzyl, methyl, or ethyl ester of 2-pipecoline carboxylate, proline, 4-hydroxyproline, 1,2,3,4-tetrahydro-3-isoquinolinecarboxylate, thiozolidine-2-carboxylate, and mixtures thereof.

18. (New) A method according to Claim 14 wherein R_2 is hydrogen or methyl.

19. (New) A method according to Claim 14 wherein said process is conducted in the presence of a solvent selected from the group consisting of tetrahydrofuran, dimethylformamide, dioxane, methylene chloride, and mixtures thereof.

20. (New) A method according to Claim 19 wherein said solvent is dioxane.

21. (New) A method according to Claim 14 wherein step (b) is conducted at a temperature of from 100 °C to 110 °C.

22. (New) A method according to Claim 3 wherein prior to step (a) said process comprises a step of forming said hydrazine compound having the formula:



wherein said step comprises reacting tert-butoxycarbonyl hydrazine with carbonyldiimidazole or thiocarbonyldiimidazole to form said hydrazine compound.

23. (New) A method according to Claim 22 wherein said hydrazine compound is used in step (a) directly without further purification.

24. (New) A method according to Claim 14 further comprising the step of isolating said hydantoin or thiohydantoin.

25. (New) A method according to Claim 19 wherein said process further comprises the step of removing said solvent.

26. (New) A method for making a hydantoin or thiohydantoin having the formula:



wherein X is oxygen or sulfur, R_1 is hydrogen, alkyl, a heterocyclic ring, an aromatic ring, or a heteroaromatic ring; R_2 is hydrogen, alkyl, a heterocyclic ring, an aromatic ring, or a heteroaromatic ring; or R_1 and R_2 can be taken together to form a fused heterocyclic ring, a fused aromatic ring, or a fused heteroaromatic ring with the hydantoin or thiohydantoin ring; said method comprising the steps of:

a) reacting a hydrazine compound having the formula:



with a resin-bound amino acid ester having the formula:



wherein the symbol:

signifies a Merrifield resin, hydroxymethyl, resin, Wang resin, or PEG resin; to form a reaction mixture; and

b) heating said reaction mixture to form said hydantoin or thiohydantoin.

27. (New) A method for making a 3-aminodihydrouracil or 3-aminodihydrothiouracil having the formula:



wherein X is oxygen or sulfur, R_1 is hydrogen, alkyl, a heterocyclic ring, an aromatic ring, or a heteroaromatic ring; R_2 is hydrogen, alkyl, a heterocyclic ring, an aromatic ring, or a heteroaromatic ring; or R_1 and R_2 can be taken together to form a fused heterocyclic ring, a fused aromatic ring, or a fused heteroaromatic ring with the 3-aminodihydrouracil or 3-aminodihydrothiouracil ring; said method comprising the steps of:

a) reacting a hydrazine compound having the formula:



with an amino acid ester having the formula:



wherein the symbol:

signifies a Merrifield resin, hydroxymethyl, resin, Wang resin, or PEG resin; to form a reaction mixture; and

b) heating said reaction mixture to form said 3-aminodihydrouracil or 3-aminodihydrothiouracil.

REMARKS

Claims 1 and 2 have been canceled without prejudice. Claims 3-27 have been added to particularly point out and distinctly claim the subject matter of the present invention. Antecedent basis for Claims 3-27 is found throughout the specification and original Claims 1 and 2.

In addition, several typographical errors in the specification have been corrected.

CONCLUSION

Applicants have made an earnest effort to place the present claims in condition for allowance. WHEREFORE, entry of the amendments to the Claims provided herewith, and allowance of Claims 3-27, as provided, are respectfully requested. In the event that issues remain prior to allowance of the noted claims, then the Examiner is invited to call:

Richard S. Echler, Sr.
Agent for Applicant
Registration No. 41,006
(513) 622-1973

to discuss any remaining issues.

Respectfully submitted,

By _____

T. David Reed
Agent for Applicants
Registration No. 32,931

26 March 2002
5299 Spring Grove Avenue
Cincinnati, Ohio 45217-1087
Phone: (513) 627-7025
FAX: (513) 627-6333

7821prel doc

13 Rec'd PCT/PTO 27 MAR 2002
10/089329

PROCESS FOR MAKING BOC-PROTECTED 3-AMINOHYDANTOINS/THIOHYDANTOINS AND 3-AMINODIHYDROURACILS/DIHYDROTHIOURACILS

Technical Field

The present invention is directed to a process for the efficient solution and solid-phase synthesis of Boc-protected 3-aminohydantoins/thiohydantoins and 3-aminodihydrouracils/dihydrothiouracils.

Background of the Invention

The present invention is directed to a novel process for synthesizing Boc-protected 3-aminohydantoins, 3-aminodihydrouracils, and their thio-substituted counterparts using a one-pot solution-phase or solid-phase process. 3-aminohydantoin and 3-aminodihydrouracil derivatives are useful in both the pharmaceutical and agrochemical industries. For example, compounds containing the 3-aminohydantoin or 3-aminodihydrouracil nucleus are useful as anticonvulsant agents, antibacterial agents, metalloprotease inhibitors, diuretic agents, and pesticides.

Synthetic routes for the preparation of 3-aminohydantoin derivatives are disclosed in the following references: Kiec-Kononowicz, K.; Zejc, A.; Byrtus, H. *Pol. J. Chem.* **1984**, *58*, 585. Lange, J. *et al. Polish Patent*, PL 123138 B1, April 30, **1984**. Wright, G. C.; Michels, J. G.; Spencer, C. F. *J. Med. Chem.* **1969**, *12*, 379-381. Bernard, L. *et al. French Patent*, 2000801, January 24, **1969**. Kobayashi, N. et al. *Japanese Patent*, 09176131 A2, July 8, **1997**. Taub, W. *U.S. Patent* 2767193, **1956**. *Chem. Abstr.*, **1957**, *51*, 5811. Szczepanski, H.; Kristinsson, H.; Maienfish, P.; Ehrenfreund, J. WO 95/18123, **1995**. Lindemann, A.; Khan, N. H.; Hofmann, K. *J. Am. Chem. Soc.*, **1952**, *74*, 476-479. Gante, J.; Lautsch, W. *Chem. Ber.*, **1964**, *97*, 994. Schlogl, K.; Derkosch, J.; Korger, G. C. *Monatsh. Chem.* **1954**, *85*, 607. Schlogl, K.; Korger, G. *Monatsh. Chem.* **1951**, *82*, 799. Davidson, J. S. *J. Chem. Soc.* **1964**, 4646-4647. Gillis, B. T.; Dain, J. G. *J. Heterocyclic Chem.* **1971**, *8*, 339-339. Wildonger, R. A.; Winstead, M. B. *J. Heterocyclic Chem.* **1967**, *4*, 981-982. Lalezari, I. *J. Heterocyclic Chem.* **1985**, *22*, 741-743. Saegusa, Y.; Harada, S.; Nakamura, S. *J. Heterocyclic Chem.* **1990**, *27*, 739-742. Milcent, R.; Akhnazarian, A.; Lensen, N. *J. Heterocyclic Chem.* **1996**, *33*, 1829-1833. Ragab, F. A.; Eid, N. M.; El-Tawab, H. A. *Pharmazie* **1997**, *52* (12), 926-929. Yoon, J; Cho, C-W; Han; H; Janda, K. D. *Chem. Comm.* **1998**, 2703-2704. However, in general the synthetic routes disclosed above involve multiple steps, require harsh reaction conditions, and/or produce relatively low yields.

Additionally, there has been growing interest in the development of solid-phase synthetic approaches to hydantoin and dihydrouracil derivatives, particularly those substituted at the *N*-1, *N*-3, and C-5 positions. Syntheses of 1-aminohydantoins and 3-aminohydantoins by solid-phase synthetic approaches are disclosed in the following references: Dewitt, S. H.; Kiely, J. S.; Stankovic, C. J.; Schroder, M. C.; Reynolds Cody, D. M.; Pavia, M. R. *Proc. Natl. Acad. Sci.* **1993**, *90*, 6909-6913. Dressman, B. A.; Spangle, L. A.; Kaldor, S. W. *Tetrahedron Lett.* **1996**, *37*, 937-940. Hanessisan, S.; Yany, R.-Y. *Tetrahedron Lett.* **1996**, *37*, 5835-5838. Kim, S. W.; Ahn, S. Y.; Koh, J. S.; Lee, J. H.; Ro, S.; Cho, H. Y. *Tetrahedron Lett.* **1997**, *38*, 4603-4606. Matthews, J.; Rivero, R. A. *J. Org. Chem.* **1997**, *62*, 6090-6092. Gong, Y-D.; Najdi, S.; Olmstead, M. M.; Kurth, M. J. *J. Org. Chem.* **1998**, *63*, 3081-3086. Xiao, X.; Ngu, K.; Chao, C.; Patel, D. V. *J. Org. Chem.* **1997**, *62*, 6968-6973. Smith, J.; Liras, J. L.; Schneider, S. E.; Anslyn, E. V. J. *J. Org. Chem.* **1996**, *61*, 8811-8813. Sim, M. M.; Ganesan, A. *J. Org. Chem.* **1997**, *62*, 3230-3233. Wilson, L. J.; Li, M.; Portlock, D. E. *Tetrahedron Lett.* **1998**, *39*, 5135-5138. Hamuro, Y.; Marshall, W. J.; Scialdone, M. A. *J. Comb. Chem.* **1999**, *1*, 163-167.

There is a continuing need for improved processes for producing 3-aminohydantoins, 3-aminodihydrouracils, and their thio-substituted counterparts.

Summary of the Invention

The present invention provides a process for the efficient assembly of Boc-protected 3-aminohydantoins/thiohydantoins and 3-aminodihydrouracils/dihydrothiouracils via a one-pot solution phase or solid phase synthesis from readily available starting materials.

Detailed Description of the Invention

Definitions and Usage of Terms

"Alkyl" is a saturated or unsaturated hydrocarbon chain having 1 to 18 carbon atoms, preferably 1 to 12, more preferably 1 to 6, more preferably still 1 to 4 carbon atoms. Alkyl chains may be straight or branched. Preferred branched alkyl have one or two branches. Unsaturated alkyl have one or more double bonds and/or one or more triple bonds. Alkyl chains may be unsubstituted or substituted with from 1 to about 4 substituents unless otherwise specified.

"Aromatic ring" is a benzene ring or a naphthlene ring.

"Carbocyclic ring" is a saturated or unsaturated hydrocarbon ring. Carbocyclic rings are not aromatic. Carbocyclic rings are monocyclic, or are fused, spiro, or bridged bicyclic ring systems. Monocyclic carbocyclic rings contain from about 4 to about 10 carbon atoms, preferably from 4 to 7 carbon atoms, and most preferably from 5 to 6

carbon atoms in the ring. Bicyclic carbocyclic rings contain from 8 to 12 carbon atoms, preferably from 9 to 10 carbon atoms in the ring. Carbocyclic rings may be unsubstituted or substituted with from 1 to about 4 substituents on the ring.

"Heteroatom" is a nitrogen, sulfur, or oxygen atom. Groups containing more than one heteroatom may contain different heteroatoms. As used herein, halogens are not heteroatoms.

"Heterocyclic ring" is a saturated or unsaturated ring containing carbon and from 1 to about 4 heteroatoms in the ring. Heterocyclic rings are not aromatic. Heterocyclic rings are monocyclic, or are fused or bridged bicyclic ring systems. Monocyclic heterocyclic rings contain from about 4 to about 10 member atoms (carbon and heteroatoms), preferably from 4 to 7, and most preferably from 5 to 6 member atoms in the ring. Bicyclic heterocyclic rings contain from 8 to 12 member atoms, preferably 9 or 10 member atoms in the ring. Heterocyclic rings may be unsubstituted or substituted with from 1 to about 4 substituents on the ring.

"Heteroaromatic ring" is an aromatic ring system containing carbon and from 1 to about 4 heteroatoms in the ring. Heteroaromatic rings are monocyclic or fused bicyclic ring systems. Monocyclic heteroaromatic rings contain from about 5 to about 10 member atoms (carbon and heteroatoms), preferably from 5 to 7, and most preferably from 5 to 6 in the ring. Bicyclic heteroaromatic rings contain from 8 to 12 member atoms, preferably 9 or 10 member atoms in the ring. Bicyclic heteroaromatic rings are ring systems wherein at least one of the two rings is a heteroaromatic ring and the other ring is a heteroaromatic ring, an aromatic ring, a carbocyclic ring, or a heterocyclic ring. Heteroaromatic rings may be unsubstituted or substituted with from 1 to about 4 substituents on the ring.

"Member atom" refers to a polyvalent atom (C, O, N, or S atom) in a chain or ring system that continues the chain or ring system. For example, in benzene the six carbon atoms are member atoms and the six hydrogen atoms are not member atoms.

Compounds Prepared Using the Present Process

The present invention is directed to a one-pot, solution-phase process for making Boc-protected 3-aminohydantoins/thiohydantoins and 3-aminodihydrouracils/dihydrothiouracils according to **Formula I** below:



Formula I

In **Formula I** above, X is O or S.

In **Formula I** above, n is 0 or 1.

In **Formula I** above, R_1 is H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, or heteroaromatic ring. When R_1 is substituted alkyl, preferred substituents include: halo, hydroxy, alkoxy, aryloxy, acyloxy, carboxy, mercapto, alkylthio, arylthio, acylthio, carbamoyl, amido, aromatic ring, heteroaromatic ring, carbocyclic ring, and heterocyclic ring.

In **Formula I** above, R_2 is H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, or heteroaromatic ring. When R_2 is substituted alkyl, preferred substituents include: halo, hydroxy, alkoxy, aryloxy, acyloxy, carboxy, alkoxycarbonyl, mercapto, alkylthio, arylthio, acylthio, amino, carbamoyl, carbamoyloxy, amido, alkoxylamido, ureido, guanidino, aryl, heteroaryl, cycloalkyl or heterocyclyl.

In **Formula I** above, when n is 0, R_1 and R_2 may instead together form a ring system; said ring system being carbocyclic ring, heterocyclic ring, or heteroaromatic ring. When n is 1, R_1 and the member carbon atom adjacent to the carbon atom containing R_2 may instead together form a ring system; said ring system being carbocyclic ring, heterocyclic ring, or heteroaromatic ring.

The Boc-protected 3-aminohydantoins/thiohydantoins and 3-aminodihydrouracils/dihydrothiouracils of the present invention may be further modified into substituted 3-aminohydantoins/thiohydantoins and 3-aminodihydrouracils/dihydrothiouracils using methods known to one of ordinary skill in the art.

Compounds which may be prepared using the present invention include, but are not limited to the following:

Carbamic acid, [2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [5-oxo-3-(phenylmethyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [4-methyl-2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [4-methyl-5-oxo-3-(phenylmethyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, ((7aS)-tetrahydro-1,3-dioxo-1*H*-pyrrolo[1,2-c]imidazol-2(3*H*)-yl-, 1,1-dimethylethyl ester.



Carbamic acid, ((7aS)-tetrahydro-1-oxo-3-thioxo-1*H*-pyrrolo[1,2-c]imidazol-2(3*H*)-yl-, 1,1-dimethylethyl ester.



Carbamic acid, (Hexahydro-1,3-dioxoimidazol[1,5-a]pyridin-2(3*H*)-yl)-, 1,1-dimethylethyl ester.



Carbamic acid, (Hexahydro-1-oxo-3-thioxoimidazol[1,5-a]pyridin-2(3*H*)-yl)-, 1,1-dimethylethyl ester.



Carbamic acid, ((10aS)-1,5,10,10a-tetrahydro-1,3-dioxoimidazol[1,5-b]isoquinolin-2(3*H*)-yl)-, 1,1-dimethylethyl ester.



Carbamic acid, ((10aS)-1,5,10,10a-tetrahydro-1-oxo-3-thioxoimidazol[1,5-b]isoquinolin-2(3*H*)-yl)-, 1,1-dimethylethyl ester.



Carbamic acid, (Tetrahydro-5,7-dioxoimidazol[5,1-b]thiazol-6(5*H*)-yl)-, 1,1-dimethylethyl ester.



Carbamic acid, (Tetrahydro-7-oxo-7-thioxoimidazol[5,1-b]thiazol-6(5*H*)-yl)-, 1,1-dimethylethyl ester.



Carbamic acid, ((6*R*,7aS)-tetrahydro-6-hydroxy-1,3-dioxo-1*H*-pyrrolo[1,2-c]imidazol-2(3*H*)-yl-, 1,1-dimethylethyl ester.



Carbamic acid, (2,5-dioxo-3-phenyl-1-imidazolidinyl)-, 1,1-dimethylethyl ester.



Carbamic acid, (5-oxo-3-phenyl-2-thioxo-1-imidazolidinyl)-, 1,1-dimethylethyl ester.



Carbamic acid, (tetrahydro-2,6-dioxo-3-(phenylmethyl)-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester.



Carbamic acid, (tetrahydro-6-oxo-3-(phenylmethyl)-2-thioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester.



Carbamic acid, (3-(2-furanylmethyl)tetrahydro-2,6-dioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester.



Carbamic acid, (3-(2-furanylmethyl)tetrahydro-6-oxo-2-thioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester.



Carbamic acid, (3-butyltetrahydro-2,6-dioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester.



Carbamic acid, (3-butyltetrahydro-6-oxo-2-thioxo-1(2*H*)-pyrimidinyl)-,1,1-dimethylethyl ester.



Carbamic acid, (tetrahydro-6-oxo-3-phenyl-2-thioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester.



Carbamic acid, (tetrahydro-6-oxo-3-(4-methoxyphenyl)-2-thioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester.



Carbamic acid, (hexahydro-1,6,8-trioxo-2*H*-pyrazinol[1,2-c]pyrimidin-7(6*H*)- yl)-, 1,1-dimethylethyl ester.



Carbamic acid, [3-[(4-methoxyphenyl)methyl)-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [3-(1,3-benzodioxol-5-ylmethyl)-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [2,5-dioxo-3-[2-(2-pyridinyl)ethyl]-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [3-[2-(5-methoxy-1*H*-indol-3-yl)ethyl]-2,5-dioxo-1-imidazolidinyl]- 1,1-dimethylethyl ester.



Carbamic acid, [3-[2-(1*H*-imidazol-4-yl)-ethyl]-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [3-[2-(1*H*-imidazol-1-yl)-ethyl]-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [3-[2-[[5-nitro-2-pyridinyl]amino]ethyl]-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [2,5-dioxo-3-[2-(1-piperidinyl)ethyl]-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [5-oxo-3-[2-(1- piperidinyl)ethyl]-2-thioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [3-[2-(1-methyl-2-pyrrolidinyl)ethyl]-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [3-[2-(2-methyl-1-piperidinyl)propyl]-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [2,5-dioxo-3-[3-(1-piperidinyl)propyl]-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [3-[3-(4-morpholinyl)propyl]-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [2,5-dioxo-3-[3-(2-oxo-1-pyrrolidinyl)propyl]-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [3-[(6,6-dimethylbicyclo[3.1.1]hept-3-yl)methyl]-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [2,5-dioxo-3-[1-(phenylmethyl)-4-piperidinyl]-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [3-[(4-methoxyphenyl)methyl)-5-oxo-2-thioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [tetrahydro-3-[(5-nitro-2-pyridinyl)amino]ethyl]-2,6-dioxo-1(2*H*)-pyrimidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [tetrahydro-3-[2-(4-morpholinyl)ethyl]-2,6-dioxo-1(2*H*)-pyrimidinyl]-, 1,1-dimethylethyl ester.



Carbamic acid, [tetrahydro-2,6-dioxo-3-[1-(phenylmethyl)-4-piperidinyl]-1(2*H*)-pyrimidinyl]-, 1,1-dimethylethyl ester.



Solution-Phase Process for Making Compounds According to Formula I

In one embodiment, the present invention provides a one-pot solution-phase process for preparing compounds according to **Formula I** above depicted below as **Scheme I**. The process depicted below in **Scheme I** requires no chromatographies (for n = 0) and a simple liquid/liquid extraction and crystallization/filtration at the end.

Scheme 1



The process depicted above in **Scheme I** begins with providing a compound according to **Formula II.** In **Formula II**, X is as defined above for **Formula I**. Compounds according to **Formula II** can be made from known starting materials and methods known to one of ordinary skill in the art. One particularly preferred method for the preparation of compounds according to **Formula II** involves slow addition of

commercially available *t*-butoxycarbonyl (Boc) hydrazine to carbonyldiimidazole (X = O) or thiocarbonyldiimidazole (X = S). Once made, compounds according to **Formula II** need not be isolated, but rather can be reacted *in situ* for the next step.

Compounds according to **Formula II** are first reacted with or amino acid esters having the following general structure:



wherein R_1 and R_2 are as defined above for **Formula I**, and R is alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, or heteroaromatic ring. Preferred R is methyl, ethyl, and benzyl. These or amino acid esters are commercially available or are made from commercially available starting materials from methods known to one of ordinary skill in the art.

The resulting intermediates according to **Sia** need not be isolated, but rather undergo intramolecular cyclization to the desired products of **Formula I** on warming. Thus, the next step in the process is heating the reaction mixture. The preferred reaction time is 8 hours and the reaction temperature is preferably kept between 60-70°C for 3-aminohydantoin derivatives (**Formula I** wherein n = 0). The preferred reaction time is >24 hours and the reaction temperature is preferably kept between 100-110°C for 3-aminodihydrouracil derivatives (**Formula I** wherein n = 1). Commonly used organic solvents are used. Preferred organic solvents include THF, DMF, dioxane, and methylene chloride. The most preferred organic solvent is dioxane.

Solid-Phase Process for Making Compounds According to Formula I

In another embodiment, the present invention provides a solid-phase process for preparing compounds according to **Formula Ia below. Formula Ia** is a subset of **Formula I** compounds.



wherein

X is O or S;

n is 0 or 1;

R_{1a} is H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, or heteroaromatic ring;

R_{2a} is H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, or heteroaromatic ring;

The solid phase process is depicted below as **Scheme II**.

Scheme II



Formula II **Siia** **Formula I**

The process depicted above in **Scheme II** begins with providing a compound according to **Formula II.** Compounds according to **Formula II** are first reacted with resin-bound or amino acid esters having the following general structure:



wherein R_{1a} and R_{2a} are as defined above for **Formula I**, and ○ is a Merrifield resin, hydroxymethyl resin, Wang resin, or PEG resin, preferably a Merrifield resin. These resin-bound or amino acid esters are made from commercially available starting materials from methods known to one of ordinary skill in the art. A preferred method for the preparation of Merrifield resin-bound or amino acid esters resins is to esterify the Merrifield resin with α-bromoacetic acid or acrylic acid. Relevant references include: Wilson, L. J.; Li, M.; Portlock, D. E. *Tetrahedron Lett.* **1998**, 39 5135-5138. Morphy, J. R.; Rankovic, Z.; Rees, D. C. *Tetrahedron Lett.* **1996**, 37 3209-3212. Kolodziej, S.; Hamper, B. C. . *Tetrahedron Lett.* **1996**, 37 5277-5280.

Compounds according to **Formula II** are preferably reacted with these resin-bound or amino acid esters at room temperature. Intermediates according to **Siia** are

then thoroughly washed to remove impurities and excess reagents. In this reaction step, common organic solvents are used. Preferred organic solvents include THF, DMF, dioxane, acetonitrile and methylene chloride. The most preferred solvent is anhydrous DMF.

Warming compounds according to **SIIa** induces intramolecular cyclization and release from the resin to provide the desired products according to **Formula I**. Thus, the next step in the process is heating the reaction mixture. The temperature of the cyclization reaction is preferably kept between about 60-70°C and the reaction time is preferably about 8-10 hours for the formation of 3-aminohydantoin derivatives (**Formula I**, wherein n = 0). The temperature of the cyclization reaction is preferably kept between about 90-95°C and the reaction time is preferably 24 hours for the formation of 3-aminodihydrouracil derivatives (**Formula I**, wherein n = 1).

This method allows for the ready preparation of 3-aminohydantoins/ thiohydantoins and 3-aminodihydrouracils/dihydrothiouracils which contain a wide variety of substituents at *N*-1, including basic groups which can be difficult to purify when made by solution methods.

The following non-limiting examples illustrate the present invention:

Example 1

Preparation of carbamic acid, [5-oxo-3-(phenylmethyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester:

To a solution of 990 mg (90%, 5.0 mmol) of thiocarbonyldiimidazole in 25 mL of 1,4-dioxane is added dropwise 0.66 g (5 mmol) of *tert*-butyl carbazate in 25 mL of 1,4-dioxane. The solution is stirred for 3 hours at room temperature, followed by the addition of *N*-benzylglycine ethyl ester 996 mg (5 mmol). The resulting mixture is heated to 60 °C for 4 hours. The dioxane is removed under reduced pressure. The residue is dissolved in EtOAc (150 mL) and washed with water (2 x 50 mL), 0.1N aqueous HCl (2 x 50 mL), dried with $MgSO_4$ and concentrated *in vacuo* to afford carbamic acid, [5-oxo-3-(phenylmethyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester (1.52 g, 95%).

Example 2

Preparation of carbamic acid, [4-methyl-5-oxo-3-(phenylmethyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester:

To a solution of 593 mg (90%, 3.0 mmol) of thiocarbonyldiimidazole in 15 mL of 1,4-dioxane is added dropwise 0.66 g (5 mmol) of *tert*-butyl carbazate in 25 mL of 1,4-

dioxane. The solution is stirred for 3 hours at room temperature, followed by the addition of *N*-benzylalanine ethyl ester 621 mg (3 mmol). The resulting mixture is heated to 60 °C for 4 hours. The dioxane is removed under reduced pressure. The residue is dissolved in EtOAc (100 mL) and washed with water (50 mL), 0.1N aqueous HCl (2 x 25 mL), dried with $MgSO_4$ and concentrated *in vacuo* to afford carbamic acid, [4-methyl-5-oxo-3-(phenylmethyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester (887 mg, 80%).

Example 3

Preparation of carbamic acid, (Tetrahydro-5,7-dioxoimidazol[5,1-b]thiazo- 6(5*H*)-yl)-, 1,1-dimethylethyl ester:

To a solution of 1.03 g (6.4 mmol) of carbonyldiimidazole in 30 mL of THF is added dropwise 0.66 g (5 mmol) of *tert*-butyl carbazate in 10 mL of THF. The solution is stirred for 4 hours at room temperature, followed by the addition of methyl thiozolidine-2-carboxlate HCl salt 920 mg (5.0 mmol). The resulting mixture is heated to reflux for 4 hours. The THF is removed under reduced pressure. The residue is dissolved in EtOAc (100 mL) and washed with water (100 mL), 0.1N aqueous HCl (100 mL), water (100 mL), dried with Na_2SO_4 and concentrated *in vacuo* to afford carbamic acid, ((7aS)-tetrahydro-5,7-dioxoimidazol[5,1-b]thiazo- 6(5*H*)-yl)-, 1,1-dimethylethyl ester (1.0 g, 74%).

Example 4

Preparation of carbamic acid, ((10aS)-1,5,10,10a-tetrahydro-1,3-dioxoimidazol[1,5-b]isoquinolin-2(3*H*)-yl)-, 1,1-dimethylethyl ester:

To a solution of 1.06 g (6.5 mmol) of carbonyldiimidazole in 25 mL of 1,4-dioxane is added dropwise 0.66 g (5 mmol) of *tert*-butyl carbazate in 25 mL of 1,4-dioxane. The solution is stirred for 3 hours at room temperature, followed by the addition of benzyl (S)-(-) 1,2,3,4-tetrahydro-3-isoquinoline carboxylate p-toluenesulfonic acid salt 2.19 g (5 mmol) and triethylamine (0.5 mL). The resulting mixture is heated to 60 °C for 4 hours. The dioxane is removed under reduced pressure. The residue is dissolved in EtOAc (150 mL) and washed with water (2 x 50 mL), 0.1N aqueous HCl (2 x 50 mL), dried with $MgSO_4$ and concentrated to 20mL *in vacuo* to give a white precipitate. The solid is filtered off and dried in *vacuo* to afford carbamic acid, ((10aS)-1,5,10,10a-tetrahydro-1,3-dioxoimidazol[1,5-b]isoquinolin-2(3*H*)-yl)-, 1,1-dimethylethyl ester (1.38 g, 87%).

Example 5

Preparation of carbamic acid, ((10aS)-1,5,10,10a-tetrahydro-1-oxo-3-thioxoimidazol[1,5-b]isoquinolin-2(3*H*)-yl)-, 1,1-dimethylethyl ester:

To a solution of 972 mg (6 mmol) of carbonyldiimidazole in 25 mL of 1,4-dioxane is added dropwise 0.66 g (5 mmol) of *tert*-butyl carbazate in 25 mL of 1,4-dioxane. The solution is stirred for 3 hours at room temperature, followed by the addition of benzyl (S)-(-) 1,2,3,4-tetrahydro-3-isoquinoline carboxylate p-toluenesulfonic acid salt 2.19 g (5 mmol) and triethylamine (0.5 mL). The resulting mixture is heated to 60 °C for 4 hours. The dioxane is removed under reduced pressure. The residue is dissolved in EtOAc (150 mL) and washed with water (2 x 50 mL), 0.1N aqueous HCl (2 x 50 mL), dried with $MgSO_4$ and concentrated to 20mL *in vacuo* to give a white precipitate. The solid is filtered off and dried in *vacuo* to afford carbamic acid, ((10aS)-1,5,10,10a-tetrahydro-1-oxo-3-thioxoimidazol[1,5-b]isoquinolin-2(3*H*)-yl)-, 1,1-dimethylethyl ester (1.56 g, 94%).

Example 6

Preparation of carbamic acid, (2,5-dioxo-3-phenyl-1-imidazolidinyl)-, 1,1-dimethylethyl ester:

To a solution of 915 mg (5.6 mmol) of carbonyldiimidazole in 15 mL of 1,4-dioxane is added dropwise 528 g (4.8 mmol) of *tert*-butyl carbazate in 15 mL of 1,4-dioxane. The solution is stirred for 2 hours at room temperature, followed by the addition of N-phenyl glycinate ethyl ester 716 mg (4.0 mmol). The resulting mixture is heated to 70 °C for 7 hours. The dioxane is removed under reduced pressure. The residue is dissolved in EtOAc (100 mL) and washed with water (50 mL), 0.1N aqueous HCl (2 x 50 mL), dried with $MgSO_4$ and concentrated to 20mL *in vacuo* to give a white precipitate. The solid is filtered off and dried in *vacuo* to afford Preparation of carbamic acid, (2,5-dioxo-3-phenyl-1-imidazolidinyl)-, 1,1-dimethylethyl ester (858 mg, 76%).

Example 7

Preparation of carbamic acid, (5-oxo-3-phenyl-2-thioxo-1-imidazolidinyl)-, 1,1-dimethylethyl ester:

To a solution of 593 mg (3.0 mmol) of thiocarbonyldiimidazole in 15 mL of 1,4-dioxane is added dropwise 396 g (3.0 mmol) of *tert*-butyl carbazate in 15 mL of 1,4-dioxane. The solution is stirred for 3 hours at room temperature, followed by the addition of N-phenyl glycinate ethyl ester 495 mg (3.0 mmol). The resulting mixture is heated to 70 °C for 7 hours. The dioxane is removed under reduced pressure. The residue is dissolved in EtOAc (100 mL) and washed with water (50 mL), 0.1N aqueous HCl (2 x 50

mL), dried with $MgSO_4$ and concentrated to afford crude product which is further purified by Biotage column (eluent: EtOAc/Hexane, 3/7). The pure product, carbamic acid, (5-dioxo-3-phenyl-2-thioxo-1-imidazolidinyl)-, 1,1-dimethylethyl ester, is obtained as semisolid material (820 mg, 81%).

Example 8

Preparation of carbamic acid, (hexahydro-1,3-dioxoimidazol[1,5-a]pyridin-2(3*H*)-yl)-, 1,1-dimethylethyl ester:

To a solution of 972 mg (6 mmol) of carbonyldiimidazole in 25 mL of 1,4-dioxane is added dropwise 792 g (6 mmol) of *tert*-butyl carbazate in 25 mL of 1,4-dioxane. The solution is stirred for 2 hours at room temperature, followed by the addition of ethyl pipercolinate 785 mg (5 mmol). The resulting mixture is heated to 60-70 °C for 4 hours. The dioxane is removed under reduced pressure. The residue is dissolved in EtOAc (150 mL) and washed with water (50 mL), 0.1N aqueous HCl (2 x 50 mL), dried with $MgSO_4$ and concentrated to afford carbamic acid, (hexahydro-1,3-dioxoimidazol[1,5-a]pyridin-2(3*H*)-yl)-, 1,1-dimethylethyl ester (1.21 g, 90%).

Example 9

Preparation of carbamic acid, (3-(phenylmethyl)tetrahydro-2,6-dioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester:

To a solution of 1.14 g (7 mmol) of carbonyldiimidazole in 50 mL of 1,4-dioxane is added dropwise 793 mg (6 mmol) of *tert*-butyl carbazate in 10 mL of 1,4-dioxane. The solution is stirred for 4 hours at room temperature, followed by the addition of *N*-benzyl--alanine ethyl ester 1.04 g (5 mmol). The resulting mixture is refluxed for 72 hours. The dioxane is removed under reduced pressure. The residue is dissolved in EtOAc, washed with H_2O, 0.1 N HCl, H_2O respectively and dried over Na_2SO_4 and concentrated *in vacuo* to afford carbamic acid, (3-(phenylmethyl)tetrahydro-2,6-dioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester (1.02 g, 64%).

Example 10

Preparation of carbamic acid, (3-(2-furanylmethyl)tetrahydro-2-oxo-6-thioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester:

To a solution of 988 mg (90%, 5.5 mmol) of thiocarbonyldiimidazole in 15 mL of 1,4-dioxane is added dropwise 660 mg (5 mmol) of *tert*-butyl carbazate in 25 mL of 1,4-dioxane. The solution is stirred for 3 hours at room temperature, followed by the addition of *N*-2-furanylmethyl- -alanine ethyl ester 985 mg (5 mmol). The resulting mixture is

refluxed for 24 hours. The dioxane is removed under reduced pressure. The residue is purified by Biotage column (eluent: EtOAc/Hexane, 6/4) to afford carbamic acid, (3-(2-furanylmethyl)tetrahydro-2-oxo-6-thioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester (1.25 g, 77%).

Example 11

Preparation of carbamic acid, (3-(2-furanylmethyl)tetrahydro-2,6-dioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester:

To a solution of 810 mg (90%, 5.0 mmol) of carbonyldiimidazole in 25 mL of 1,4-dioxane is added dropwise 660 mg (5 mmol) of *tert*-butyl carbazate in 25 mL of 1,4-dioxane. The solution is stirred for 3 hours at room temperature, followed by the addition of *N*-2-furanylmethyl -alanine ethyl ester 985 mg (5 mmol). The resulting mixture is refluxed for 24 hours. The dioxane is removed under reduced pressure. The residue is purified by Biotage column (eluent: EtOAc/Hexane, 6/4) to afford carbamic acid, (3-(2-furanylmethyl)tetrahydro-2,6-dioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester (1.01 g, 65%).

Example 12

Preparation of carbamic acid, (3-butyltetrahydro-6-oxo-2-thioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester:

To a solution of 984 mg (90%, 5.5mmol) of thiocarbonyldiimidazole in 25 mL of 1,4-dioxane is added dropwise 0.66 g (5 mmol) of *tert*-butyl carbazate in 25 mL of 1,4-dioxane. The solution is stirred for 3 hours at room temperature, followed by the addition of *N*-n-butyl- -alanine methyl ester 795 mg (5 mmol). The resulting mixture is refluxed for 24 hours. The dioxane is removed under reduced pressure. The residue is dissolved in EtOAc (100 mL) and washed with water (50 mL), 0.1N aqueous HCl (2 x 25 mL), dried with $MgSO_4$ and concentrated *in vacuo* to afford carbamic acid, (3-butyltetrahydro-6-oxo-2-thioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester (1.23 g, 81%).

Example 13

Preparation of carbamic acid, (3-butyltetrahydro-2,6-dioxo -1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester:

To a solution of 1.14 g (7.0 mmol) of carbonyldiimidazole in 30 mL of 1,4-dioxane is added dropwise 0.79 g (6 mmol) of *tert*-butyl carbazate in 20 mL of 1,4-dioxane. The solution is stirred for 4 hours at room temperature, followed by the addition

of *N*-n-butyl- -alanine methyl ester 795 mg (5 mmol). The resulting mixture is refluxed for 40 hours. The dioxane is removed under reduced pressure. The residue is dissolved in EtOAc, washed with H_2O, 0.1 N HCl, H_2O respectively and dried over Na_2SO_4 and concentrated *in vacuo* to afford carbamic acid, (3-butyltetrahydro-2,6-dioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester (1.28 g, 84%).

Example 14

Preparation of carbamic acid, (tetrahydro-6-oxo-3-(4-methoxyphenyl)-2-thioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester:

To a solution of 988 mg (90%, 5.5 mmol) of thiocarbonyldiimidazole in 25 mL of 1,4-dioxane is added dropwise 0.66 g (5 mmol) of *tert*-butyl carbazate in 25 mL of 1,4-dioxane. The solution is stirred for 3 hours at room temperature, followed by the addition of *N*-(4-methoxyphenyl)- -alanine ethyl ester 1.12 g (5 mmol). The resulting mixture is refluxed for 48 hours. The dioxane is removed under reduced pressure. The residue is dissolved in EtOAc (100 mL) and washed with water (50 mL), 0.1N aqueous HCl (2 x 25 mL), dried with $MgSO_4$ and concentrated *in vacuo* to afford carbamic acid, (tetrahydro-6-oxo-3-(4-methoxyphenyl)-2-thioxo-1(2*H*)-pyrimidinyl)-, 1,1-dimethylethyl ester (0.59 g, 33%).

Example 15

Preparation of Merrifield resin-bound -bromoacetate ester :

To a solution of DIC (diisopropylcarbodiimide) (31g, 253 mmol), -bromoacetic acid (35g, 246 mmol) and Merrifield resin (50 g, 33.5 mmol, loading level: 0.67 mmol/g) in methylene chloride (600 mL) is added DMAP (1g, 8.1 mmol). The resulting mixture is shaken at room temperature for 24 hours. Resin is collected on a glass filter and washed two times each with DMF, MeOH, DCM. The resin is dried to give the Merrifield resin-bound -bromoacetate ester (53.1 g, yield 98%).

Example 16

Preparation of carbamic acid, [2,5-dioxo-3-[2-(2-pyridinyl)ethyl]-1-imidazolidinyl]-, 1,1-dimethylethyl ester:

Merrifield resin-bound -bromoacetate ester (2 g, loading 0.67 mmol/g) is treated with DMF (40 mL) and 2-(2-aminoethyl)pyridine (810 mg, 6.6 mmol) and allowed to shake for 24 hours at room temperature. Washing two times each with DMF, MeOH, DCM afforded resin. This is then treated with Boc-hydrazinecarbonylimidazole

(6.6 mmol) in 40 mL of DMF (prepared *in situ* according to the process of solution-phase chemistry which is described above in **Scheme 1**) at room temperature for 10 hours and washed two times each with DMF, MeOH, DCM to afford a resin according to **Siia** (where n = 0, X = O, R_1 = 2-(2-pyridinyl)ethyl). The resin is then placed in a flask with 40 mL of DMF and heated to 65-70°C for 8 hours. After cooling, the resin is filtered, washed with small amount of DMF, DCM and MeOH and the combined filtrates concentrated. The residue is dissolved in 30 mL of MeOH and filtered, concentrated *in vacuo* to give desired product, carbamic acid, [2,5 dioxo-3-[2-(2-pyridinyl)ethyl]-1-imidazolidinyl]-, 1,1-dimethylethyl ester (183 mg, 63%).

Example 17

Preparation of carbamic acid, [3-[2-(5-methoxy-1*H*-indol-3-yl)ethyl]-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester:

Merrifield resin-bound -bromoacetate ester (2 g, loading 0.67 mmol/g) is treated with DMSO (60 mL) and 5-methoxytryptamine (1.0 g, 5.26 mmol) and allowed to shake for 24 hours at room temperature. Washing two times each with DMF, MeOH, DCM affords the resin. This is then treated with Boc-hydrazinecarbonylimidazole (5.2 mmol) in 60 mL of DMF (prepared *in situ* according to the process of solution-phase chemistry which is described above in **Scheme 1**) at room temperature for 10 hours and washed two times each with DMF, MeOH, DCM to afford a resin according to **Siia** (where n = 0, X = O, R_1 = 2-(5-methoxy-1*H*-indol-3-yl)ethyl). The resin is then placed in a flask with 50 mL of DMF and heated to 60-70°C for 8 hours. After cooling, the resin is filtered, washed two times each with DMF, DCM and MeOH and the combined filtrates concentrated. The residue is dissolved in 30 mL of MeOH and filtered, concentrated *in vacuo* to give desired product, carbamic acid, [3-[2-(5-methoxy-1*H*-indol-3-yl)ethyl]-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester (310 mg, 61%).

Example 18

Preparation of carbamic acid, [3-[2-(1*H*-imidazol-4-yl)-ethyl]-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester:

Merrifield resin-bound -bromoacetate ester (2 g, loading 0.67 mmol/g) is treated with DMSO (60 mL) and histamine (733 mg, 6.6 mmol) and allowed to shake for 24 hours at room temperature. Washing two times each with DMF, MeOH, DCM afford the resin. This is then treated with Boc-hydrazinecarbonylimidazole (6.6 mmol) in 60 mL of DMF (prepared *in situ* according to the process of solution-phase chemistry which is described above in **Scheme 1**) at room temperature for 10 hours and washed two times

each with DMF, MeOH, DCM to afford a resin according to **Siia** (where n = 0, X = O, R_1 = 2-(1*H*-imidazol-4-yl)-ethyl). The resin is then placed in a flask with 50 mL of DMF and heated to 60-70°C for 8 hours. After cooling, the resin is filtered, washed with small amount of DMF, DCM and MeOH and the combined filtrates concentrated. The residue is dissolved in 30 mL of MeOH and filtered, concentrated *in vacuo* to give desired product, carbamic acid, [3-[2-(1*H*-imidazol-4-yl)-ethyl]-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester (202 mg, 50%).

Example 19

Preparation of carbamic acid, [3-[2-(1-methyl-2-pyrrolidinyl)ethyl]-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester:

The Merrifield resin-bound -bromoacetate ester (3 g, loading 0.67 mmol/g) is treated with DMSO (60 mL) and 2-(2-aminoethyl)-1-methylpyrrolidine (1.42 g, 10 mmol) and allowed to shake for 24 hours at room temperature. Washing two times each with DMF, MeOH, DCM affords the resin. This is then treated with Boc-hydrazinecarbonylimidazole (10 mmol) in 60 mL of DMF (prepared *in situ* according to the process of solution-phase chemistry which is described above in **Scheme 1**) at room temperature for 10 hours and washed two times each with DMF, MeOH, DCM to afford a resin according to **Siia** (where n = 0, X = O, R_1 = 2-(1-methyl-2-pyrrolidinyl)ethyl). The resin is then placed in a flask with 50 mL of DMF and heated to 60-70°C for 8 hours. After cooling, the resin is filtered, washed with small amount of DMF, DCM and MeOH and the combined filtrates concentrated. The residue is dissolved in 30 mL of MeOH and filtered, concentrated *in vacuo* to give desired product (445 mg, 69%).

Example 20

Preparation of carbamic acid, [3-[2-[[5-nitro-2-pyridinyl]amino]ethyl]-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester:

Merrifield resin-bound -bromoacetate ester (3 g, loading 0.67 mmol/g) is treated with DMSO (60 mL) and 2-(2-aminoethylamino)-5-nitropyridine (1.82 g, 10 mmol) and allowed to shake for 24 hours at room temperature. Washing two times each with DMF, MeOH, DCM affords the resin. This is then treated with Boc-hydrazinecarbonylimidazole (10 mmol) in 60 mL of DMF (prepared *in situ* according to the process of solution-phase chemistry which is described above in **Scheme 1**) at room temperature for 10 hours and washed two times each with DMF, MeOH, DCM to afford a resin according to **Siia** (where n = 0, X = O, R_1 = 2-[[5-nitro-2-pyridinyl]amino]ethyl). The resin is then placed in a flask with 50 mL of DMF and heated to 60-70°C for 8 hours. After cooling, the resin

is filtered, washed two times each with DMF, DCM and MeOH and the combined filtrates concentrated. The residue is dissolved in 30 mL of MeOH and filtered, concentrated *in vacuo* to give desired product, carbamic acid, [3-[2-[[5-nitro-2-pyridinyl]amino]ethyl]-2,5-dioxo-1-imidazolidinyl]-, 1,1-dimethylethyl ester (440 mg, 58.5%).

Example 21

Preparation of carbamic acid, [2,5-dioxo-3-[2-(1-piperidinyl)ethyl]-1-imidazolidinyl]-, 1,1-dimethylethyl ester:

Merrifield resin-bound -bromoacetate ester (2 g, loading 0.67 mmol/g) is treated with DMSO (60 mL) and 1-(2-aminoethyl)piperidine (0.88 g, 6.7 mmol) and allowed to shake for 24 hours at room temperature. Washing two times each with DMF, MeOH, DCM affords the resin. This is then treated with Boc-hydrazinecarbonylimidazole (6.5 mmol) in 50 mL of DMF (prepared *in situ* according to the process of solution-phase chemistry which is described above in **Scheme 1**) at room temperature for 10 hours and washed two times each with DMF, MeOH, DCM to afford a resin according to **Siia** (where n = 0, X = O, R_1 = 2-(1-piperidinyl)ethyl). The resin is then placed in a flask with 30 mL of DMF and heated to 60-70°C for 8 hours. After cooling, the resin is filtered, washed two times each with DMF, DCM and MeOH and the combined filtrates concentrated. The residue is dissolved in 30 mL of MeOH and filtered, concentrated *in vacuo* to give desired product, carbamic acid, [2,5-dioxo-3-[2-(1-piperidinyl)ethyl]-1-imidazolidinyl]-, 1,1-dimethylethyl ester (262 mg, 59%).

Example 22

Preparation of Merrifield resin-bound acrylate ester:

To a solution of DIC (15g, 119 mmol), acrylic acid (17g, 208 mmol) and Merrifield resin (25 g, 200 mmol, loading level: 0.80 mmol/g) in methylene chloride (300 mL) is added DMAP (0.5g, 4 mmol). The resulting mixture is shaken at room temperature for 24 hours. Resin is collected on a glass filter and washed two times each with DMF, MeOH, DCM. The resin is dried to give the Merrifield resin-bound acrylate ester (37 g, yield 94%).

Example 23

Preparation of carbamic acid, [tetrahydro-3-[(5-nitro-2-pyridinyl)amino]ethyl]-2,6-dioxo-1(2*H*)-pyrimidinyl]-, 1,1-dimethylethyl ester:

Merrifield resin-bound acrylate ester (2 g, loading 0.8 mmol/g) is treated with DMSO (50 mL) and 2-(2-aminoethylamino)-5-nitropyridine (1.46 g, 8.0 mmol) and allowed to shake for 24 hours at room temperature. Washing two times each with DMF, MeOH, DCM affords the resin. This is then treated with Boc-hydrazinecarbonylimidazole (8 mmol) in 40 mL of DMF (prepared *in situ* according to the process of solution-phase chemistry which is described above in **Scheme 1**) at room temperature for 24 hours and washed two times each with DMF, MeOH, DCM to afford a resin according to **Siia** (where n = 1, X = O, R_1 = (5-nitro-2-pyridinyl)aminoethyl). The resin is then placed in a flask with 40 mL of DMF and heated to 95°C for 24 hours. After cooling, the resin is filtered, washed two times each with DMF, DCM and MeOH and the combined filtrates concentrated. The residue is dissolved in 40 mL of EtOAc and filtered, concentrated *in vacuo* to give desired product carbamic acid, [tetrahydro-3-[(5-nitro-2-pyridinyl)amino]ethyl]-2,6-dioxo-1(2*H*)-pyrimidinyl]-, 1,1-dimethylethyl ester (289 mg, 46%).

Example 24

Preparation of carbamic acid, [tetrahydro-3-[2-(4-morpholinyl)ethyl]-2,6-dioxo-1(2*H*)-pyrimidinyl]-, 1,1-dimethylethyl ester:

Merrifield resin-bound acrylate ester (2 g, loading, 8.0 mmol/g) is treated with DMSO (50 mL) and 4-(2-aminoethyl)morpholine (1.04 g, 8 mmol) and allowed to shake for 24 hours at room temperature. Washing two times each with DMF, MeOH, DCM affords the resin. This is then treated with Boc-hydrazinecarbonylimidazole (8 mmol) in 40 mL of DMF (prepared *in situ* according to the process of solution-phase chemistry which is described above in **Scheme 1**) at room temperature for 24 hours and washed two times each with DMF, MeOH, DCM to afford a resin according to **Siia** (where n = 1, X = O, R_1 = 2-(4-morpholinyl)ethyl). The resin is then placed in a flask with 40 mL of DMF and heated to 95°C for 24 hours. After cooling, the resin is filtered, washed two times each with DMF, DCM and MeOH and the combined filtrates concentrated. The residue is dissolved in 40 mL of EtOAc and filtered, concentrated *in vacuo* to give desired product carbamic acid, [tetrahydro-3-[2-(4-morpholinyl)ethyl]-2,6-dioxo-1(2*H*)-pyrimidinyl]-, 1,1-dimethylethyl ester (229 mg, 42%).

Example 25

Preparation of carbamic acid, [tetrahydro-2,6-dioxo-3-[1-(phenylmethyl)-4-piperidinyl]-1(2*H*)-pyrimidinyl]-, 1,1-dimethylethyl ester:

Merrifield resin-bound acrylate ester (2 g, loading, 8.0 mmol/g) is treated with DMSO (50 mL) and 4-amino-1-benzyl-piperidine (1.52 g, 8 mmol) and allowed to shake for 24 hours at room temperature. Washing two times each with DMF, MeOH, DCM affords the resin. This is then treated with Boc-hydrazinecarbonylimidazole (8 mmol) in 40 mL of DMF (prepared *in situ* according to the process of solution-phase chemistry which is described above in **Scheme 1**) at room temperature for 24 hours and washed two times each with DMF, MeOH, DCM to afford a resin according to **Siia** (where n = 1, X = O, R_1 = 1-(phenylmethyl)-4-piperidinyl). The resin is then placed in a flask with 40 mL of DMF and heated to 95°C for 24 hours. After cooling, the resin is filtered, washed two times each with DMF, DCM and MeOH and the combined filtrates concentrated. The residue is dissolved in 20-30 mL of MeOH and filtered, concentrated *in vacuo* to give desired product carbamic acid, [tetrahydro-2,6-dioxo-3-[1-(phenylmethyl)-4-piperidinyl]-1(2*H*)-pyrimidinyl]-, 1,1-dimethylethyl ester (289 mg, 45%).

Example 26

Preparation of carbamic acid, [tetrahydro-6-oxo-3-(phenylmethyl)-2-thioxo-1(2*H*) -pyrimidinyl]-, 1,1-dimethylethyl ester:

Merrifield resin-bound acrylate ester (2 g, loading, 8.0 mmol/g) is treated with DMSO (50 mL) and benzyl amine (1.025 g, 9 mmol) and allowed to shake for 24 hours at room temperature. Washing two times each with DMF, MeOH, DCM affords the resin. This is then treated with Boc-hydrazinecarbonylimidazole (6 mmol) in 50 mL of DMF (prepared *in situ* according to the process of solution-phase chemistry which is described above in **Scheme 1**) at room temperature for 24 hours and washed two times each with DMF, MeOH, DCM to afford a resin according to **Siia** (where n = 1, X = S, R_1 = benzyl). The resin is then placed in a flask with 50 mL of DMF and heated to 95°C for 24 hours. After cooling, the resin is filtered, washed two times each with DMF, DCM and MeOH and the combined filtrates concentrated. The residue is dissolved in 40 mL of EtOAc and filtered, concentrated *in vacuo* to give desired product carbamic acid, [tetrahydro-6-oxo-3-(phenylmethyl)-2-thioxo-1(2*H*) -pyrimidinyl]-, 1,1-dimethylethyl ester (117 mg, 22%).

WHAT IS CLAIMED IS:

1. A method for making a compound according having the following structure:



wherein

X is O or S;

n is 0 or 1;

R_1 is H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, or heteroaromatic ring;

R_2 is H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, or heteroaromatic ring; and

when n is 0, R_1 and R_2 may instead together form a ring system; said ring system being carbocyclic ring, heterocyclic ring, or heteroaromatic ring; or when n is 1, R_1 and the member carbon atom adjacent to the carbon atom containing R_2 may instead together form a ring system; said ring system being carbocyclic ring, heterocyclic ring, or heteroaromatic ring;

said method comprising the steps of:

a) providing a compound having the following structure



wherein X is as defined above;

b) reacting the compound provided in step a above with an or amino acid ester having the structure:



wherein R_1 and R_2 are as defined above and R is alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, or heteroaromatic ring; and

c) heating the reaction mixture.

2. A method for making a compound according having the following structure:



wherein

X is O or S;

n is 0 or 1;

R_{1a} is H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, or heteroaromatic ring;

R_{2a} is H, C_1-C_8 alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, or heteroaromatic ring;

said method comprising the steps of:

a) providing a compound having the following structure



wherein X is as defined above;

b) reacting the compound provided in step a above with a resin-bound or amino acid ester having the structure:



wherein R_1 and R_2 are as defined above and is a Merrifield resin, hydroxymethyl resin, Wang resin, or PEG resin; and

c) heating the reaction mixture.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 April 2001 (19.04.2001)

PCT

(10) International Publication Number
WO 01/27087 A2

(51) International Patent Classification[7]: C07D 233/00

(21) International Application Number: PCT/US00/27503

(22) International Filing Date: 5 October 2000 (05.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/158,660 8 October 1999 (08.10.1999) US

(71) Applicant *(for all designated States except US)*: **THE PROCTER & GAMBLE COMPANY** [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **WU, Shengde** [US/US]; 7563 Lakota Springs Drive, West Chester, OH 45069 (US). **JANUSZ, John, Michael** [US/US]; 7385 Desert Springs Court, West Chester, OH 45069 (US).

(74) Agents: **REED, T., David** et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217-1087 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/27087 A2

(54) Title: PROCESS FOR MAKING BOC-PROTECTED 3-AMINOHYDANTOINS/THIOHYDANTOINS AND 3-AMINODIHYDROURACILS/DIHYDROTHIOURACILS

(57) Abstract: The present invention provides a process for the efficient assembly of Boc-protected 3-aminohydantoins/thiohydantoins and 3-aminodihydrouracils/dihydrothiouracils via a one-pot solution phase or solid phase synthesis from readily available starting materials.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the U.S. National Phase Entry
Under 35 USC 371 from
International Application of
WU, Shengde et al.
Int'l. Application No. PCT/US00/27503
Filed in the RO/US on 05 October 2000
Entitled: **Process For Making Boc-Protected 3-Aminohydantoins/Thiohydantoins and 3-Aminodihydrouracils/Dihydrothiouracils**

ASSOCIATE POWER OF ATTORNEY

Assistant Commissioner for Patents
Box PCT
Washington, D.C. 20231

Dear Sir:

You are requested to recognize M. P. McMahon (Registration No. 34,673), T. A. Boozer (Registration No. 45,406), D. V. Upite (Registration No. 47,147), and R. S. Echer (Registration No. 41,006) of The Procter & Gamble Company, Cincinnati, Ohio, as well as all attorneys/agents associated with the customer number listed below as Associate Attorneys to prosecute this application, to make alterations and amendments therein, and to transact all business in the Patent Office connected with the application or with the patent granted thereupon.

Please address all future communications to:

R. S. Echler, Patent Agent
Customer Number 27752

Respectfully submitted for Applicants,

By _____
T. David Reed
Agent for Applicant
Registration No. 32,931

Cincinnati, Ohio
25 March 2002
(513) 627-7025/FAX 627-6333

DECLARATION COMBINED WITH POWER OF ATTORNEY

Attorney Docket No. 7821

As a below named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated below next to my name.

I believe I am the original and first inventor or inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled Process For Making Boc-Protected 3-Aminohydantoins/Thiohydantoins And 3-Aminodihyrouracils/Dihydrothiouracils
the specification of which

(check one) [] is attached hereto.
[X] was filed on October 5, 2000 as United States Application No. or PCT International Application No. PCT/US 00/27503
and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
(Number)	(Country)	(Day/Month/Year Filed)	[] Yes	[] No

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

60/158,660	October 8, 1999		
Application Serial No.	Filing Date	Application Serial No.	Filing Date

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s), or §365(c) of any PCT International application designating the United States of America, listed below:

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (If applicable)

As named inventor, I hereby appoint the registered practitioners associated with customer number 27752 to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO: Customer Number 27752

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-05 Full name of sole or first inventor Shengde (NMN) Wu
Inventor's signature _____ 4/1/02
Date

Residence 7563 Lakota Springs Drive, West Chester, OH 45069 OH
Citizenship USA
Mailing Address 7563 Lakota Springs Drive, West Chester, OH 45069

2-05 Full name of second inventor, if any, John Michael Janusz
Inventor's signature _____ 4/1/02
Date

Residence 7385 Desert Springs Court, West Chester, OH 45069 OH
Citizenship USA
Mailing Address 7385 Desert Springs Court, West Chester, OH 45069

Full name of third inventor, if any __
Inventor's signature _____
Date

Residence _____
Citizenship _____
Mailing Address _____

Full name of fourth inventor, if any _
Inventor's signature _____
Date

Residence _____
Citizenship _____
Mailing Address _____

(DeclwithCustomerNumber.doc)
(Revised 11/12/01)